Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James E Herndon

Showing results (1-10 of 285) with videos related to

Pageof 29
Sort By:
Journal of Neurosurgery|January 22, 2011
Resection of vestibular schwannomasJohn H Sampson, James E Herndon
Journal of Neurosurgery|October 9, 2012
Subarachnoid hemorrhage trialsAli Zomorodi, James E Herndon, John H Sampson
Lung Cancer (Amsterdam, Netherlands)|May 14, 2004
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancerSendhil Kumar Cheran, James E Herndon, Edward F Patz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendationsEdward F Patz, Stephen J Swensen, James E Herndon
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 5, 2020
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide"Mary Lou Affronti, James E Herndon, Mallika P Patel
Radiology|May 9, 2002
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PETEdith M Marom, Sarah Sarvis, James E Herndon, et al.
Springerplus|July 9, 2016
Insomnia and its associations in patients with recurrent glial neoplasmsMatthew E Robertson, Frances McSherry, James E Herndon, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)Antonius A Miller, James E Herndon, Lin Gu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group BHedy L Kindler, James E Herndon, Chunfeng Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2007
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrenceJoerg Gauger, Edward F Patz, R Edward Coleman, et al.
Pageof 29

Showing results (1-10 of 285) with videos related to

Sort By:
Pageof 29
Journal of Neurosurgery|January 22, 2011
Resection of vestibular schwannomasJohn H Sampson, James E Herndon
Journal of Neurosurgery|October 9, 2012
Subarachnoid hemorrhage trialsAli Zomorodi, James E Herndon, John H Sampson
Lung Cancer (Amsterdam, Netherlands)|May 14, 2004
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancerSendhil Kumar Cheran, James E Herndon, Edward F Patz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendationsEdward F Patz, Stephen J Swensen, James E Herndon
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 5, 2020
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide"Mary Lou Affronti, James E Herndon, Mallika P Patel
Radiology|May 9, 2002
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PETEdith M Marom, Sarah Sarvis, James E Herndon, et al.
Springerplus|July 9, 2016
Insomnia and its associations in patients with recurrent glial neoplasmsMatthew E Robertson, Frances McSherry, James E Herndon, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)Antonius A Miller, James E Herndon, Lin Gu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group BHedy L Kindler, James E Herndon, Chunfeng Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2007
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrenceJoerg Gauger, Edward F Patz, R Edward Coleman, et al.
Pageof 29